Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HTR1B | P28222 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1623557 | 0.98 | KDM4E (0.79) | KDM4EL3MBTL1TDP1CA12CA1 | |
| Hydrochloric Acid SCHEMBL4729179 | 0.96 | KDM4E (0.76) | KDM4EL3MBTL1TDP1CA12CA1 | |
| SCHEMBL6649844 | 0.89 | L3MBTL1 (0.67) | KDM4EL3MBTL1TDP1CA12CA1 | |
| Phosphoric Acid SCHEMBL28097933 | 0.89 | KDM4E (0.60) | KDM4EL3MBTL1TDP1LMNAHTR1B | |
| SCHEMBL31050988 | 0.89 | KDM4E (0.95) | KDM4EL3MBTL1TDP1LMNAHTR1B | |
| SCHEMBL8834938 | 0.89 | KDM4E (0.95) | KDM4EL3MBTL1TDP1LMNAHTR1B | |
| SCHEMBL9179777 | 0.88 | L3MBTL1 (0.67) | KDM4EL3MBTL1TDP1CA12CA1 | |
| SCHEMBL7060496 | 0.88 | L3MBTL1 (0.70) | KDM4EL3MBTL1TDP1CA12CA1 | |
| Hydrochloric Acid SCHEMBL4383401 | 0.88 | L3MBTL1 (0.65) | KDM4EL3MBTL1TDP1CA12CA1 | |
| SCHEMBL1592409 | 0.86 | CA12 (0.68) | L3MBTL1TDP1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 372 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118561764-A | Preparation method and crystal form of PDE4 inhibitor clobiprofen | 兰晟生物医药(苏州)有限公司 | 2024-08-30 | — | — | CN | claimed |
| CN-113861047-B | Synthesis method of 2- (2-methoxyphenoxy) ethylamine | 杭州国瑞生物科技有限公司 | 2024-05-14 | — | — | CN | claimed |
| CN-115232034-B | Synthesis method of tamsulosin hydrochloride | 上药康丽（常州）药业有限公司 | 2024-02-20 | — | — | CN | claimed |
| CN-115232034-A | Method for synthesizing tamsulosin hydrochloride | 上药康丽（常州）药业有限公司 | 2022-10-25 | — | — | CN | claimed |
| CN-114105884-A | Preparation method and crystal form of PDE4 inhibitor clobiplane | 兰晟生物医药(苏州)有限公司 | 2022-03-01 | — | — | CN | claimed |
| CN-113861047-A | Synthetic method of 2- (2-methoxyphenoxy) ethylamine | 杭州国瑞生物科技有限公司 | 2021-12-31 | — | — | CN | claimed |
| CN-107827849-B | 6- [ 2-hydroxy-3- (alkylamino) propoxy ] benzofuran compound and application thereof | 沈阳药科大学 | 2020-06-02 | — | — | CN | claimed |
| CN-107857748-B | 5- [ 2-hydroxy-3- (alkylamino) propoxy ] benzofuran compound and application thereof | 沈阳药科大学 | 2020-06-02 | — | — | CN | claimed |
| CN-111217741-A | Fluorine-substituted monocarbazole derivative, preparation method and application thereof | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2020-06-02 | — | — | CN | claimed |
| US-9487533-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2016-11-08 | — | — | US | claimed |
| EP-1299101-A4 | CARVEDILOL | TEVA PHARMA (IL) | 2004-06-16 | — | — | EP | claimed |
| WO-2004041783-A1 | PROCESS FOR PREPARATION OF CARVEDILOL | ZENTIVA, A.S. (SK) | 2004-05-21 | — | — | WO | claimed |
| US-6699997-B2 | REACTING 4-(OXIRAN-2-YLMETHOXY)-9H- CARBAZOLE WITH 2-(2-METHOXYPHENOXY)ETHYLAMINE TO PRODUCE CARVEDILOL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-03-02 | — | — | US | claimed |
| EP-1299101-A1 | CARVEDILOL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-04-09 | — | — | EP | claimed |
| US-20020143045-A1 | Carvedilol | TEVA PHARMACEUTICALS USA, INC. | 2002-10-03 | — | — | US | claimed |
| WO-2002000216-A1 | CARVEDILOL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-01-03 | — | — | WO | claimed |
| US-5801179-A | TREATMENT OF MIGRAINES, HYPOTENSION, VENOUS INSUFFICIENCY | JANSSEN PHARMACEUTICA, NV (BE) | 1998-09-01 | — | — | US | claimed |
| EP-0127099-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE CARBAZOLE DERIVATIVES, R- AND S-CARBAZOLE DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | Roche Diagnostics GmbH (DE) | 1987-05-20 | — | — | EP | claimed |
| EP-0034432-B1 | SULFAMOYL-SUBSTITUTED PHENETHYLAMINE DERIVATIVES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS, CONTAINING THEM | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1984-04-25 | — | — | EP | claimed |
| US-4379788-A | HYPOTENSIVES, ANTIARRHYTHMIA, B-BLOCKERS | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-04-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143045-A1 | Carvedilol | REN, ADRB1, ADRB2 | KDM4E 3067/4885L3MBTL1 4133/4885TDP1 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.